Compounded GLP-1s in Summer 2026: What Your Doctor Needs to Know About Safety

The Compounding Market in Context

Despite the arrival of lower-cost oral GLP-1s in 2026 (Wegovy pill at $149/month, orforglipron at $149/month), compounded semaglutide and tirzepatide remain a significant part of the market. Licensed telehealth providers offer compounded injectable semaglutide in the $99-$179/month range, making it the most affordable entry point for many patients — particularly those without insurance coverage.

The safety landscape, however, requires informed navigation. Not all compounding pharmacies operate at the same standard, and the distinction matters for your health.

503A vs. 503B: What These Designations Mean

The Federal Food, Drug, and Cosmetic Act establishes two categories of compounding pharmacies under sections 503A and 503B. Understanding the difference helps you evaluate the safety of your medication source:

503A Pharmacies

These are traditional compounding pharmacies that prepare medications based on individual patient prescriptions. They are state-licensed and state-regulated. Each preparation is made for a specific patient with a specific prescription. There is no federal requirement for current good manufacturing practice (cGMP) compliance, though many states impose their own standards. Quality is variable.

503B Outsourcing Facilities

These are federally registered facilities that can produce larger batches of compounded medications without patient-specific prescriptions. They are subject to FDA inspection, must follow cGMP standards, and are required to report adverse events. Quality standards are closer to (but not identical to) those of traditional pharmaceutical manufacturers.

How to Verify a Compounding Pharmacy

Your prescriber should be able to tell you which pharmacy prepares your medication. Once you have the name, verify it through these channels:

• LegitScript certification. LegitScript is an independent verification service that evaluates pharmacy compliance with applicable laws and standards. A LegitScript-certified pharmacy has undergone external review. Many reputable telehealth platforms require LegitScript certification from their pharmacy partners.
• State Board of Pharmacy. Every compounding pharmacy must hold a valid license from the state pharmacy board where it operates. You can verify this through your state's board website. An active license in good standing is the baseline — no exceptions.
• FDA registration (503B only). If the pharmacy claims 503B status, you can verify its federal registration on the FDA's outsourcing facility database.
• NABP accreditation. The National Association of Boards of Pharmacy offers accreditation programs for compounding pharmacies. This is an additional quality signal, though not all legitimate pharmacies pursue it.

Red Flags in Compounding Pharmacy Marketing

Be cautious of providers or pharmacies that:

• Claim their compounded GLP-1 is "FDA-approved" (it is not — compounded medications by definition are not FDA-approved)
• Do not identify which pharmacy prepares the medication
• Ship medications without a valid prescription from a licensed provider
• Offer prices that seem significantly below the market ($50/month or less for injectable semaglutide should raise questions about quality)
• Advertise "generic semaglutide" (there is no generic — semaglutide is still under patent; compounded semaglutide is a different regulatory category)
• Cannot provide a Certificate of Analysis for their products upon request

What to Ask Your Telehealth Provider

• Which pharmacy compounds my medication, and are they 503A or 503B?
• Is the pharmacy LegitScript-certified?
• Can I receive a Certificate of Analysis for my specific batch?
• What quality testing does the pharmacy perform on each batch?
• What is the pharmacy's track record with state and federal regulators? (Any warning letters, recalls, or enforcement actions?)